Win32 Virus Removal

Houston is known for energy, but the city is also building a budding technology sector. The world's oil capital is home to scores of hopeful entrepreneurs developing new Web sites, software, medical devices, clean technologies and other innovations. Research at the Texas Medical Center, NASA, local universities and in the energy industry, for example, has given birth to new ventures. Here's one of an occasional set of snapshots of local tech startups. Time will tell if they take off.

Ensysce Biosciences

• Elevator pitch: Using tiny particles called carbon nanotubes to deliver treatments to individual cancer cells.

• The idea: Drugs delivered through the bloodstream have a hard time entering cells. But nanotubes, which are 1 to 2 nanometers in diameter and can carry large therapy molecules, pass easily out of the bloodstream and directly through cell membranes into cancer cells. Ensysce Biosciences says it has developed a way to attach a cancer therapy, known as short interfering RNA, to nanotubes so they can enter cancer cells and prevent the tumors from growing.

• Users: None. The company plans to start studies required by the FDA during the next six to 12 months so it can then gain approval to start clinical trials.

• The brains: Bob Gower founded the company in 2008 as spinoff of Carbon Nanotechnologies, set up to commercialize discoveries by a co-owner, the late Richard Smalley, in nanotechnology. Ensysce CEO Lynn Kirkpatrick co-founded and served as head of ProlX Pharmaceuticals before it was acquired in 2006.

• The competition: Some companies are working on engulfing cancer treatments in nano particles that are more than 100 nanometers in diameter, and thus more difficult to enter into cells, Kirkpatrick said. Competitors include California-based Calando Pharmaceuticals and Canada-based Tekmira Pharmaceuticals.

• The money: Founder Gower has invested a little more than $1 million, Kirkpatrick said, and the state’s Emerging Technology Fund has committed $1.5 million if the company meets certain milestones. The company has already received $250,000 from the fund.

DNAtrix

• Elevator pitch: Using a virus to attack cancer cells.

• The idea: Viruses are good at killing the cells they infect, so DNAtrix is putting one to work on brain tumors. The company says it mutates the adenovirus, one cause of the common cold, so that it has a special coating of peptides, one of the building blocks of protein. The coat allows the virus to stick to cancer cells. The virus is also mutated so that it doesn’t replicate in healthy cells. The mutated virus, known as delta24-RGD, is then injected directly into the tumor, where it replicates in the cancer cells until they burst.

• Users: The company is conducting clinical trials on nine brain cancer patients at the University of Texas
M.D. Anderson Cancer Center and plans to include up to 48 patients in the initial trial.

• The brains: Frank Tufaro took the CEO position six months ago. Prior to that he served on the company’s board and founded Vancouver-based biotech company NeuroVir, which eventually was sold to Germany-based MediGene. The therapy was developed by a research team led by scientists at the M.D. Anderson Cancer Center.

• The competition: There are a handful of companies working on cancer-killing viruses, including Massachusetts-based BioVex, which is working on a virus that attacks skin cancer. Philadelphia based Catherex is studying a modified herpes virus.

• The money: The company has received $500,000 from the state’s Emerging Technology Fund and is eligible to receive $500,000 more if it meets certain milestones. DFJ Mercury has invested about $480,000 in venture capital and the Marcus Foundation has given $2 million. The company also received $4.5 million in federal grants for clinical production and testing.

Laser Tissue Welding

• Elevator pitch: Using a laser to fuse tissue and stop bleeding without stitches.

• The idea: Stitches can stop bleeding but can take a while to heal and can’t be used on all tissue. Laser Tissue Welding has developed a device it says uses a laser to heat a solder made from proteins found in blood plasma, which helps hasten the healing and allow surgeons to cut the most delicate issues. Right now, the company is focusing on using the technology to repair livers after a hepatectomy, or removal of liver tissue. Founder Yasmin Wadia envisions the device being used to help repair liver and kidney tissues damaged after the removal of cancerous tumors.

• Users: None. The devices has been tested on animals and is awaiting FDA approval to begin clinical trials.

• The brains: Wadia developed the solder and technique while working as a research fellow at the Oregon Medical Laser Center. Prior to founding the company, she worked as a researcher in Houston.

• The competition: Traditional stitches.

• The money: Wadia has invested $500,000 in cash and received $160,000 from the state’s Emerging Technology Fund. The company has also received $1.3 million in federal grants.

purva.patel@chron.com

Would you like to enjoy hassle-free computing? You will certainly say yes. Then you must install an antivius software in your computer. It is seen that viruses and malicious objects are the key reason behind most of the computer problems. Viruses are small software programs that come mostly through internet and affect the computer. It corrupts data and even crashes the operating system or even the hard disk. Not just that, there are also viruses that are used by the hackers for hacking your sensitive personal information. So, to enjoy hassle-free computing you must install an antivirus program. You can also get in touch with a computer repair company for technical support. There are many such companies that offer virus removal support to the computer users.

For secure computing it is strongly recommended to install authentic version of the operating system. It is commonly seen that the user is using the pirated version of the operating system where he is unable to update it. Using pirated software always enhances the chance of virus infection and can be the prime reason of identity theft.

But when it comes to choose an antivirus program, most of the computer users face problem. There are a number of antivirus vendors who protect their consumers’ interest by offering latest update every now and then. Installing the anti virus might not always resolve the issue. For instance, if your computer is already virus affected, installing the antivirus will not resolve the issue. You need to run a full compute scan to find the infected files and heal them.

Before buying any antivirus software it is better to try with their trial version. There are many antivirus vendors that offer trial versions. You can start using their trial version and if you find the software useful, go for the full version. Avast, AVG, Macafee, Symantec, Norton, etc. are some of the most renowned names in the domain of anti virus software.

Microsoft also offers an exclusive antivirus tool namely the Microsoft Windows Malicious Software Removal Tool. This software works with Windows 7, Windows Vista as well as Windows XP, Windows 2000, and Windows Server 2003 computers. It is very effective to remove infections. When the diagnosis and healing process is over, it displays a full report describing the outcome. Here you get to see which malicious software was detected and removed.

Operating system providers offer updates and patches in regular interval to protect the users from virus infection. You must install the updates whenever available. It is suggested to check the automatic update option of your OS on so that these updates and patches could be automatically installed. You can access the automatic update option through control panel. Click on Start →Control Panel→ Security Center → Automatic Updates → Check Automatic radio button → Ok.

Another most important thing you should remember, don’t open any email attachment if it is sent by an unknown sender. In many cases viruses come in disguise with the attachments. So, think twice before clicking.

There are many technical support service providers that offer Virus Removal Support. You can consult an expert to get assistance in this regard.

AAP

A senior United Nations (UN) official has called for the removal of immigration restrictions that can prevent HIV-positive people from relocating to Australia.

UNAIDS chief Michel Sidibe said Australia should follow the USA and China which had recently removed their travel restrictions affecting people who were HIV positive.

Mr Sidibe, in Australia to attend a major UN summit in Melbourne next week, said he would raise the issue in talks with the federal government over the coming days.

"To know that in Australia, we have a restriction for people living with HIV to come and to stay ... is a little bit painful for me," Mr Sidibe said.

"I will ask them (Prime Minister Julia Gillard and other officials) - I think it is something that needs to come through the due processes of your country, but it is something that Australia should deliver on."

Permanent visa applicants aged 15 years or older in Australia are required to have a HIV-AIDS test, and residency can then be denied on the grounds of the high cost of treatment.

Mr Sidibe said travel bans and residency restrictions had the effect of further entrenching the prejudice and disadvantage faced by HIV-positive people and, ultimately, they hindered the global response to the virus.

He also gave an address that said the global effort to curb the spread of HIV had reached a critical point where years of hard-fought gain could be lost.

"I think we are at the best of times, but unfortunately we are also at the worst of times, in the fight against HIV-AIDS," Mr Sidibe told the audience at the Lowy Institute for International Policy in Sydney on Friday.

On the positive side, he said the virus had prompted a cultural shift across Africa where it was now socially acceptable for parents to have candid discussions about sex with their adolescent children.

The number of impoverished HIV-positive people in treatment programs also jumped from around 500,000 five years agoto now more than five million, while significant declines were evident in the rate of new infections and mother-to-child infections.

On the negative side, he said world leaders were due to meet in October to allocate the next tranche of funding to a global pool used to treat HIV, malaria and tuberculosis and $US20 billion was needed.

"I am scared by what I am seeing now, for the first time in 15 years, a reduction in funding allocation," Mr Sidibe said.

"Any reduction in funding will be translating into a reduction in services already available today."

There are now 33.4 million people worldwide living with HIV while there are 2.7 million new infections, and two million related deaths, every year.

Only 40 per cent of those infected know of their HIV-positive status.

SAN DIEGO, Aug. 26 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled: "Use of the Aethlon Hemopurifier® in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."  The Medicity is a $360 million multi-specialty medical institute recently established on a 43-acre campus to be a premier center of medical tourism in India. The Aethlon Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system.  A clinical goal of the Aethlon-Medicity study will be to demonstrate that the Hemopurifier® is able to accelerate the benefit of HCV standard of care (SOC) drug regimens. Therapeutic filtration at the outset of SOC improves early virus reduction kinetics to levels associated with that of patients most likely to achieve a sustained viral response, which is the goal of HCV therapy. Additionally, lower quantities of HCV in circulation at the outset of SOC correlate with increased cure rates.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

(Photo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

"We are grateful for this opportunity to show the pharmaceutical industry, infected patients, and shareholders that our Hemopurifier® can enhance the capabilities of drug regimens without adding additional drug toxicity and interaction risks", stated Aethlon Chairman and CEO, Jim Joyce. "Beneficial outcomes will set the stage for the early commercialization of our technology and should recalibrate industry viewpoints on addressing infectious disease conditions."

Upon the demonstration of early treatment benefit, Aethlon plans to advance commercialization through the Medicity and other regional treatment centers in India. In this regard, the company has entered into an agreement with GVK Biosciences (GVK BIO) to expand the opportunity for Aethlon to commercialize its Hemopurifier® treatment technology at three to five new clinical centers in India.  GVK BIO is Asia's leading Discovery Research and Development organization. The HCV treatment opportunity for Aethlon is significant as greater than 20 million of the estimated 180 million people infected with HCV worldwide reside in India.  Based on patient feedback, Aethlon also believes that citizens of other nations may chose to travel to India to seek treatments that could resolve their HCV infection.

Aethlon further disclosed that the principal investigator of the clinical program, which has been registered with the Clinical Trials Registry of India, will be Vijay Kher, M.D., Chairman of the Department of Nephrology at the Medanta Kidney & Urology Institute. Dr. Kher previously served as the principal investigator of Hemopurifier® human studies to treat HCV at the Apollo and Fortis Hospital in Delhi, India. These studies demonstrated safety and effectiveness of the Hemopurifier® to reduce viral load in the absence of drug therapy. Patients enrolled in the Medicity study will receive a maximum of six Hemopurifier® treatments within the first week of initiating SOC drug therapy. In addition to monitoring for improved acceleration of viral load reduction at the outset of SOC, another primary endpoint will focus on rapid viralogic response (RVR) which is defined as undetectable viral load 30 days after SOC initiation. On average, approximately 15% of patients who initiate SOC therapy achieve a RVR.  Yet, those able to achieve a RVR have a greater than 88% likelihood of achieving a sustained viralogic response. The initiation of patient enrollment for the Medicity is conditional upon maintaining the treatment protocols approved by the MIEC and that clinical endpoint / efficacy assessment be further clarified by the principal investigator. Aethlon has also agreed to give consideration to compensating enrolled patients for lost wages while receiving Hemopurifier® treatment and other consideration should a material adverse event occur as a result of Hemopurifier® therapy.

About Aethlon Medical

At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.  However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union.  In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3. Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4. Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not,  the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

SOURCE Aethlon Medical, Inc.

RELATED LINKS
http://www.aethlonmedical.com

Have you heard of the latest virus to terrorize PC users? Security Suite is a false spyware detector that is from the same family as AV Security Suite and the recent badware Antivir Solution Pro. This rogue program creeps its way into your PC and continually alerts you that your computer is loaded with viruses, spyware, and keyloggers. In reality, the software itself is opening you up to more threats, and the longer it corrupts your PC, the worse the effects can be. What the hackers who created this virus are hoping for as that users buy a “full license” so that they can steal credit card numbers, and at worst, personal identities. We must get rid of Security Suite as quickly as possible for these reasons.

You’ll be able to tell you are infected with this virus if you’ve received messages such as “Antivirus software alert, INFILTRATION ALERT

Your computer is being attacked by an internet virus. It could be a password-stealing attack, trojan – dropper or similar. Threat: BankerFox.A. Do you want to block this attack? Yes or No”. If you’ve seen this or a similar “Windows Security Alert” popping up in your taskbar, then it’s time to take action.

Security Suite also has a way of blocking your programs from opening and redirecting your internet searches to sites that contain malware. To avoid falling for this, you will need to boot up in Safe Mode, by tapping F8 at startup.

To remove Security Suite you will have to either go about it manually or automatically. I recommend automatic removal tools to beginners and pros alike because of the simplicity and effectiveness of it.

Having said that, manual removal involves digging into your system’s registry, namely in the HKEY_CURRENT_USER and HKEY_LOCAL_MACHINE folders and deleting all values associated with the Security Suite virus. A full listing can be found at my site. You will then need to delete related files, kill related processes, and block related websites.

If you are using an automatic method, it’s as simple as installing the software and clicking the Scan button. What’s even more valuable is the active scanner that software will enact, so you no longer need to worry while visiting websites or downloading files. You can be sure that another virus in this same family of viruses is coming along shortly.

Sick of viruses compromising your PC and your personal safety? Diagnose your PC and remove Security Suite right away.

Bob Walker is a veteran IT consultant with over twenty years of experience in the industry. He’s helped clean up the computers of everyone from fortune 500 organizations to individual users and families. His website is dedicated to anti-spyware and virus removal research, where he ranks the most efficient anti-spyware and anti-virus programs currently available.

http://www.spyware-review.net

Security firm Comodo is billing its upcoming "GeekBuddy" software as "your own personal geek, anytime." Summed up, that's exactly what GeekBuddy purports to be, offering a bonanza of tech related help, from virus detection/removal to email setup, and even optimizing your PC to run a little greener.

"GeekBuddy is the easiest way to get instant support with common problems which keep computers from functioning at peak performance," Comodo claims. "Our next-generation computer support service combines hands-on support with Comodo software."

You can think of GeekBuddy as a support service and software rolled into one. Comodo promises its technicians will be on standby 24/7 "to perform all problem diagnoses and repairs via a remote connection," giving users constant access to a technician to help with all those mundane tasks your family usually calls you up with in middle of the night.

GeekBuddy will ship in September with an estimated street price of $50/year, with a 30-day free trial available now.

Image Credit: Comodo